Crisaborole in dermatology
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20243880Keywords:
Atopic dermatitis, Crisaborole, Psoriasis, Phosphodiesterase-4, VitiligoAbstract
Crisaborole, though initially approved for the treatment of mild to moderate atopic dermatitis, has found its application in treatment of various other inflammatory dermatological conditions including psoriasis, vitiligo, stasis dermatitis, inflammatory verrucous epidermal nevus and more. This is due to the involvement of enzyme phosphodiesterase-4 and cyclic adenosine monophosphate (cAMP) in the pathogenesis of these disorders. Sources of study material included PubMed, National Library of Medicine, DermNet, Journal of the American Academy of Dermatology, manufacturer prescribing information and article bibliographies.This review article was prepared to show that crisaborole can be effectively used in treating those inflammatory dermatological disorders (as off-label indications) which are unresponsive to their first line treatment options. The side effects are minimal and tolerable. The only limitation is that the number of studies and case reports with crisaborole are very limited. Crisaborole seems to have promising results in the management of various inflammatory dermatological conditions with minimal side effects.
Metrics
References
Dina Coronado B, Zane LT, Coronado D. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390-6.
McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis. J Pharm Technol. 2019;35(4):172-8. DOI: https://doi.org/10.1177/8755122519844507
Eucrisa® (crisaborole) ointment, 2%, for topical use. New York, NY: Anacor Pharmaceuticals/Pfizer. 2017.
Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: A phase 1b, open‐label, maximal‐use systemic exposure study. Pediatr Dermatol. 2016;33(4):380-7. DOI: https://doi.org/10.1111/pde.12872
Draelos ZD, Ports WC, Vlahos B, Yeoh T, Wu-Linhares D, Brown MB, et al. Skin permeation and penetration of crisaborole when coapplied with emollients. J Am Acad Dermatol. 2020;1;83(6):1801-3. DOI: https://doi.org/10.1016/j.jaad.2020.03.114
Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, et al. Safety, effectiveness and pharmacokinetics of crisaborole in infants aged 3 to< 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21:275-84. DOI: https://doi.org/10.1007/s40257-020-00510-6
De A, Chakraborty D, Grisilda BN, Chaudhuri S, Godse K, Dhar S. Efficacy and safety of crisaborole ointment in pediatric atopic dermatitis: A 4-week open-label study. Ind J Skin Aller. 2024;3(1):60. DOI: https://doi.org/10.25259/IJSA_45_2023
Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023;24(4):623-35. DOI: https://doi.org/10.1007/s40257-023-00780-w
Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther. 2013;3:1-5. DOI: https://doi.org/10.1007/s13555-013-0023-0
Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;1;82(2):360-5. DOI: https://doi.org/10.1016/j.jaad.2019.06.1288
Nagui N, Gaballah B, Rashed L, Sany I. Evaluation of phosphodiesterase 4 enzyme levels in lesional skin and serum of vitiligo patients. J Egypt Women’s Dermatol Soc. 2021;1;18(3):186-90. DOI: https://doi.org/10.4103/jewd.jewd_20_21
Tam I, Kahn JS, Rosmarin D. Repigmentation in a patient with vitiligo on crisaborole 2% ointment. JAAD Case Rep. 2021;1;11:99-101. DOI: https://doi.org/10.1016/j.jdcr.2021.03.028
Tausend W, Hoyer P, Arnold M, Wagner K, Ross L, Goodwin BP, et al. Successful treatment of vitiligo with crisaborole 2% ointment. Skin J Cutan Med. 2019;11;3(2):111-3. DOI: https://doi.org/10.25251/skin.3.2.47
Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2022;17:213.
Peña SM, Oak AS, Smith AM, Mayo TT, Elewski BE. Topical crisaborole is an efficacious steroid‐sparing agent for treating mild‐to‐moderate seborrhoeic dermatitis. J Europ Acad Dermatol Venereol. 2020;1;34:12. DOI: https://doi.org/10.1111/jdv.16673
Terrell J, Hogeling M. 44569 Improvement of ILVEN with Crisaborole Use. Journal of the American Academy of Dermatology. 2023;89(3):179. DOI: https://doi.org/10.1016/j.jaad.2023.07.716
Barney E, Prose NS, Ramirez M. Inflammatory linear verrucous epidermal nevus treated successfully with crisaborole ointment in a 5‐year‐old boy. Pediatric dermatology. 2019;36(3):404-5. DOI: https://doi.org/10.1111/pde.13793
Li L. Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia. Revista da Associação Médica Brasileira. 2023;17;69:97-100. DOI: https://doi.org/10.1590/1806-9282.20220801
Petty AJ, Emge DA, Blanchard SK, Selim MA, Scoggins K, Liu B, et al. Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea. J Am Acad Dermatol. 20231;89(2):390-2. DOI: https://doi.org/10.1016/j.jaad.2023.03.052
Tancredi V, Buononato D, Caccavale S, Di Brizzi EV, Di Caprio R, Argenziano G, et al. New perspectives in the management of chronic hand eczema: lessons from pathogenesis. International J Mol Sci. 2023;27;25(1):362. DOI: https://doi.org/10.3390/ijms25010362
Kahn JSM, Grossman-Kranseler JS, Zancanaro p. Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review. Dermatitis. 2021;32:141-3. DOI: https://doi.org/10.1097/DER.0000000000000793
Silverberg JI, Kirsner RS, Margolis DJ, Tharp M, Myers DE, Annis K, et al. Efficacy and safety of crisaborole ointment, 2%, in participants aged≥ 45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study. J Am Acad Dermatol. 2024;1;90(5):945-52. DOI: https://doi.org/10.1016/j.jaad.2023.12.048
Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Advances in therapy. 2017;34:1594-609. DOI: https://doi.org/10.1007/s12325-017-0542-7
Lynde CW, Bergman J, Fiorillo L, Guenther L, Joseph M, Grant JK, et al. Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings. Supplement to STL. 2020;1;25(3).
Liang Y, Liang J, Huang Q, Tian X, Shao L, Xia M, et al. Knuckle pads successfully treated with 2% crisaborole ointment combined with triamcinolone acetonide and neomycin plaster: a case report. Clinical, Cosmetic and Investigational Dermatol. 2023;31:1893-7. DOI: https://doi.org/10.2147/CCID.S414268
Henning C, Meyers S, Swift R, Eades B, Bussell L, Spektor TM, et al. Efficacy of topical use crisaborole 2% ointment for treatment of necrobiotic xanthogranuloma associated with multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. 2020;1;20(8):e492-5. DOI: https://doi.org/10.1016/j.clml.2020.03.016
Downloads
Published
How to Cite
Issue
Section
